The Experts below are selected from a list of 8712 Experts worldwide ranked by ideXlab platform

Maria Laura Foddai - One of the best experts on this subject based on the ideXlab platform.

  • autologous pure platelet rich plasma dermal injections for facial skin rejuvenation clinical instrumental and flow cytometry assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUNDPlatelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation.OBJECTIVETo evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.MATERIALS AND METHODSTw

  • Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUND: Platelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation. OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples. MATERIALS AND METHODS: Twelve patients underwent 3 sessions of PRP injection at 1-month intervals. The clinical and instrumental outcomes were evaluated before (T0) and 1 month (T1) after the end of Treatment by means of transepidermal water loss, corneometry, Cutometer, Visioscan, and Visioface. A flow cytometry characterization on PRP and peripheral blood (PB) samples was performed. RESULTS: Clinical and patient evaluation showed improvement of skin texture. Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved. No difference between PRP and PB lymphocyte immunological asset was observed. A leukocyte population (mainly CD3) and neutrophils depletion were documented in all the PRP samples. CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation. Flow cytometry showed no variability among the PRP samples using a reproducible separation system and a low content in proinflammatory cells. Although a pilot study, it may be helpful for future investigations on PRP cellularity.

Norma Cameli - One of the best experts on this subject based on the ideXlab platform.

  • autologous pure platelet rich plasma dermal injections for facial skin rejuvenation clinical instrumental and flow cytometry assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUNDPlatelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation.OBJECTIVETo evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.MATERIALS AND METHODSTw

  • Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUND: Platelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation. OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples. MATERIALS AND METHODS: Twelve patients underwent 3 sessions of PRP injection at 1-month intervals. The clinical and instrumental outcomes were evaluated before (T0) and 1 month (T1) after the end of Treatment by means of transepidermal water loss, corneometry, Cutometer, Visioscan, and Visioface. A flow cytometry characterization on PRP and peripheral blood (PB) samples was performed. RESULTS: Clinical and patient evaluation showed improvement of skin texture. Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved. No difference between PRP and PB lymphocyte immunological asset was observed. A leukocyte population (mainly CD3) and neutrophils depletion were documented in all the PRP samples. CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation. Flow cytometry showed no variability among the PRP samples using a reproducible separation system and a low content in proinflammatory cells. Although a pilot study, it may be helpful for future investigations on PRP cellularity.

Cora N Sternberg - One of the best experts on this subject based on the ideXlab platform.

  • castration resistant prostate cancer current and Emerging Treatment strategies
    Drugs, 2010
    Co-Authors: Giuseppe Di Lorenzo, Carlo Buonerba, Sabino De Placido, Riccardo Autorino, Cora N Sternberg
    Abstract:

    Until very recently, docetaxel was the only approved agent in castration-resistant prostate cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years, several new agents with promising activity and a favourable toxicity profile have been developed and clinically investigated in the fields of hormonal, cytotoxic, targeted and immune therapy. In particular, recent results from two large phase III trials of sipuleucel-T and cabazitaxel show that these two agents significantly prolong overall survival in CRPC. Indeed, sipuleucel-T has recently been approved by the US FDA for the Treatment of CRPC. Many other pharmaceuticals, which are presented in this review, have been investigated recently or are being investigated in phase III trials and might prove to be effective in the future. Reviewed articles are discussed in light of the innovations in study design brought by the Prostate Cancer Clinical Trials Working Group (PCWG2), which updated the Prostate-Specific Antigen Working Group (PCWG1) guidelines, in order to allow better identification of potentially active drugs in clinical trials.

  • Castration-resistant prostate cancer: Current and Emerging Treatment strategies
    Drugs, 2010
    Co-Authors: Giuseppe Di Lorenzo, Carlo Buonerba, Sabino De Placido, Riccardo Autorino, Cora N Sternberg
    Abstract:

    Until very recently, docetaxel was the only approved agent in castration-resistant prostate cancer (CRPC) and other effective therapeutic options are urgently needed. In recent years, several new agents with promising activity and a favourable toxicity profile have been developed and clinically investigated in the fields of hormonal, cytotoxic, targeted and immune therapy. In particular, recent results from two large phase III trials of sipuleucel-T and cabazitaxel show that these two agents significantly prolong overall survival in CRPC. Indeed, sipuleucel-T has recently been approved by the US FDA for the Treatment of CRPC. Many other pharmaceuticals, which are presented in this review, have been investigated recently or are being investigated in phase III trials and might prove to be effective in the future. Reviewed articles are discussed in light of the innovations in study design brought by the Prostate Cancer Clinical Trials Working Group (PCWG2), which updated the Prostate-Specific Antigen Working Group (PCWG1) guidelines, in order to allow better identification of potentially active drugs in clinical trials. © 2010 Adis Data Information BV. All rights reserved.

Maria Mariano - One of the best experts on this subject based on the ideXlab platform.

  • autologous pure platelet rich plasma dermal injections for facial skin rejuvenation clinical instrumental and flow cytometry assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUNDPlatelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation.OBJECTIVETo evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.MATERIALS AND METHODSTw

  • Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUND: Platelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation. OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples. MATERIALS AND METHODS: Twelve patients underwent 3 sessions of PRP injection at 1-month intervals. The clinical and instrumental outcomes were evaluated before (T0) and 1 month (T1) after the end of Treatment by means of transepidermal water loss, corneometry, Cutometer, Visioscan, and Visioface. A flow cytometry characterization on PRP and peripheral blood (PB) samples was performed. RESULTS: Clinical and patient evaluation showed improvement of skin texture. Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved. No difference between PRP and PB lymphocyte immunological asset was observed. A leukocyte population (mainly CD3) and neutrophils depletion were documented in all the PRP samples. CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation. Flow cytometry showed no variability among the PRP samples using a reproducible separation system and a low content in proinflammatory cells. Although a pilot study, it may be helpful for future investigations on PRP cellularity.

Salvatore Masi - One of the best experts on this subject based on the ideXlab platform.

  • autologous pure platelet rich plasma dermal injections for facial skin rejuvenation clinical instrumental and flow cytometry assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUNDPlatelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation.OBJECTIVETo evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples.MATERIALS AND METHODSTw

  • Autologous Pure Platelet-Rich Plasma Dermal Injections for Facial Skin Rejuvenation: Clinical, Instrumental, and Flow Cytometry Assessment
    Dermatologic Surgery, 2017
    Co-Authors: Norma Cameli, Iole Cordone, Elva Abril, Maria Mariano, Salvatore Masi, Maria Laura Foddai
    Abstract:

    BACKGROUND: Platelet-rich plasma (PRP) is an Emerging Treatment in dermatology recently proposed for skin rejuvenation. OBJECTIVE: To evaluate the efficacy and safety of autologous pure PRP dermal injections on facial skin rejuvenation, investigating the cellularity of PRP samples. MATERIALS AND METHODS: Twelve patients underwent 3 sessions of PRP injection at 1-month intervals. The clinical and instrumental outcomes were evaluated before (T0) and 1 month (T1) after the end of Treatment by means of transepidermal water loss, corneometry, Cutometer, Visioscan, and Visioface. A flow cytometry characterization on PRP and peripheral blood (PB) samples was performed. RESULTS: Clinical and patient evaluation showed improvement of skin texture. Skin gross elasticity, skin smoothness parameters, skin barrier function, and capacitance were significantly improved. No difference between PRP and PB lymphocyte immunological asset was observed. A leukocyte population (mainly CD3) and neutrophils depletion were documented in all the PRP samples. CONCLUSION: This instrumental study demonstrated that PRP poor in leukocytes can provide objective improvements in skin biostimulation. Flow cytometry showed no variability among the PRP samples using a reproducible separation system and a low content in proinflammatory cells. Although a pilot study, it may be helpful for future investigations on PRP cellularity.